Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

cancer immunotherapy; TCGA; mutations; copy number variations; microRNAs; PD-1; PD-L1; hepatocellular carcinoma; predictive factors; immunotherapy; immune checkpoint inhibition; check-point inhibitors; liver disease; outcome; biomarkers; combination immunotherapy; immune-related adverse events (irAEs); hepatocellular carcinoma (HCC); alpha fetoprotein response; immune checkpoint inhibitor; unresectable hepatocellular carcinoma; a disintegrin and metalloprotease 9; nivolumab; natural killer; CTLA-4; combination therapy; PD-1 antibody; PD-L1 antibody; anti-VEGF inhibitor; molecular classification; immune phenotype; stem cell marker; oncogenic signal; β-catenin; genetic alteration; liver cancer; effectiveness; safety; HCC; molecular-targeted agent; TACE; tyrosine kinase inhibitor; CD14+ cells; programmed death 1 ligands; translational approaches; combination therapies; therapy resistance; predictive markers; tissue-resident memory CD8 T cells; immune checkpoint blockade